Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors--eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.
LeMaistre
C F
CF
Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.
Rosenblum
M G
MG
Reuben
J M
JM
Parkinson
D R
DR
Meneghetti
C M
CM
Parker
K
K
Shaw
J P
JP
Deisseroth
A B
AB
Woodworth
T
T
D004167:Diphtheria Toxin / Q000097:blood / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000097:blood / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000097:blood / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins